CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

--"The 2025 forecast will command the most attention in the annual accounts," Hansen said. "The addition of production capacity will continue to be the guiding principle for the full-year forecast." ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...

Donald Trump is executing a shock-and-awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...